Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Neurodegenerative diseases are a common cause of morbidity and cognitive impairment in older adults. Most clinicians who care for the elderly are not trained to diagnose these conditions, perhaps other than typical Alzheimer's disease (AD). Each of these disorders has varied epidemiology, clinical symptomatology, laboratory and neuroimaging features, neuropathology, and management. Thus, it is important that clinicians be able to differentiate and diagnose these conditions accurately. This review summarizes and highlights clinical aspects of several of the most commonly encountered neurodegenerative diseases, including AD, frontotemporal dementia (FTD) and its variants, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and Huntington's disease (HD). For each condition, we provide a brief overview of the epidemiology, defining clinical symptoms and diagnostic criteria, relevant imaging and laboratory features, genetics, pathology, treatments, and differential diagnosis.

[1]  J. Kornak,et al.  Amyloid Vs Fdg-pet in the Differential Diagnosis of Ad And , 2022 .

[2]  G. Campanella,et al.  Suicide risk in Huntington's disease. , 1993, Journal of medical genetics.

[3]  A. Takeda,et al.  [18F]FDG-PET study in dementia with lewy bodies and alzheimer's disease , 2001, Progress in Neuro-psychopharmacology and Biological Psychiatry.

[4]  Jane S. Paulsen,et al.  Depression and stages of Huntington's disease. , 2005, The Journal of neuropsychiatry and clinical neurosciences.

[5]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[6]  Nick C. Fox,et al.  Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration , 2011, Brain : a journal of neurology.

[7]  E. Tolosa,et al.  Premotor signs and symptoms of multiple system atrophy , 2012, The Lancet Neurology.

[8]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[9]  D. Craufurd,et al.  Psychiatric disorders in preclinical Huntington’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  J. Diehl-Schmid,et al.  The epidemiology of frontotemporal dementia , 2013, International review of psychiatry.

[11]  D. S. Babu Multiple-system atrophy. , 2015, The New England journal of medicine.

[12]  I Litvan,et al.  Association of an extended haplotype in the tau gene with progressive supranuclear palsy. , 1999, Human molecular genetics.

[13]  A. Hofman,et al.  Familial aggregation of Alzheimer's disease and related disorders: a collaborative re-analysis of case-control studies. , 1991, International journal of epidemiology.

[14]  Nick C Fox,et al.  Symptom onset in autosomal dominant Alzheimer disease , 2014, Neurology.

[15]  H. Paulson,et al.  Huntington's Disease (HD): Degeneration of Select Nuclei, Widespread Occurrence of Neuronal Nuclear and Axonal Inclusions in the Brainstem , 2014, Brain pathology.

[16]  R. Shiwach Psychopathology in Huntington's disease patients , 1994, Acta psychiatrica Scandinavica.

[17]  N. Kumar,et al.  The Sydney Multicenter Study of Parkinson's Disease: The Inevitability of Dementia at 20 years , 2009 .

[18]  C. Jack,et al.  Dementia with Lewy bodies and Alzheimer disease , 2010, Neurology.

[19]  B. L. Miller,et al.  The natural history of temporal variant frontotemporal dementia , 2005, Neurology.

[20]  Kristine Yaffe,et al.  Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. , 2005, JAMA.

[21]  Marian DiFiglia,et al.  Huntington Disease , 1998 .

[22]  A. Bava,et al.  Frontotemporal Dementia: Paroxetine as a Possible Treatment of Behavior Symptoms , 2002, European Neurology.

[23]  N. Hattori,et al.  CLINICOPATHOLOGIC STUDY OF A SNCA GENE DUPLICATION PATIENT WITH PARKINSON DISEASE AND DEMENTIA , 2008, Neurology.

[24]  Frederik Barkhof,et al.  The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. , 2015, Brain : a journal of neurology.

[25]  P. Ljubenkov,et al.  A Clinical Guide to Frontotemporal Dementias. , 2016, Focus.

[26]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[27]  H. Engler,et al.  In vivo amyloid imaging with PET in frontotemporal dementia , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  J. Hodges,et al.  Behavioural symptoms in progressive supranuclear palsy and frontotemporal dementia , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[29]  D W Dickson,et al.  Atrophy of superior cerebellar peduncle in progressive supranuclear palsy , 2003, Neurology.

[30]  K. Ishii,et al.  Voxel-based morphometric comparison between early- and late-onset mild Alzheimer's disease and assessment of diagnostic performance of z score images. , 2005, AJNR. American journal of neuroradiology.

[31]  B. Dubois,et al.  “Applause sign” helps to discriminate PSP from FTD and PD , 2005, Neurology.

[32]  K. Leenders,et al.  Is FDG‐PET a useful tool in clinical practice for diagnosing corticobasal ganglionic degeneration? , 2003, Movement disorders : official journal of the Movement Disorder Society.

[33]  N. Quinn,et al.  Multiple system atrophy: A review of 203 pathologically proven cases , 1997, Movement disorders : official journal of the Movement Disorder Society.

[34]  M. Weiner,et al.  Cognition and anatomy in three variants of primary progressive aphasia , 2004, Annals of neurology.

[35]  R Brookmeyer,et al.  Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. , 1998, American journal of public health.

[36]  Mathias Jucker,et al.  Neurodegenerative diseases: expanding the prion concept. , 2015, Annual review of neuroscience.

[37]  Yong-Hee Han,et al.  Progression of subcortical atrophy and iron deposition in multiple system atrophy: a comparison between clinical subtypes , 2015, Journal of Neurology.

[38]  Alexander Münchau,et al.  Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY , 2011, PLoS currents.

[39]  F. Sherriff,et al.  Memantine for dementia. , 2005, The Cochrane database of systematic reviews.

[40]  N. Herrmann,et al.  Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. , 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[41]  F. Scaravilli,et al.  Pure akinesia as initial presentation of PSP: a clinicopathological study. , 2008, Parkinsonism & related disorders.

[42]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[43]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[44]  K Patterson,et al.  Focal cortical presentations of Alzheimer's disease. , 2007, Brain : a journal of neurology.

[45]  Philip Scheltens,et al.  The clinical profile of right temporal lobe atrophy. , 2004, Brain : a journal of neurology.

[46]  Sonja W. Scholz,et al.  SNCA variants are associated with increased risk for multiple system atrophy , 2009, Annals of neurology.

[47]  Grant D. Huang,et al.  Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. , 2010, The New England journal of medicine.

[48]  Joost Dekker,et al.  Community occupational therapy for older patients with dementia and their care givers: cost effectiveness study , 2008, BMJ : British Medical Journal.

[49]  R. Staudinger,et al.  Teaching NeuroImages: “Penguin” or “hummingbird” sign and midbrain atrophy in progressive supranuclear palsy , 2009, Neurology.

[50]  M Schwaiger,et al.  Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease , 2009, Neurology.

[51]  K Patterson,et al.  Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. , 2000, Brain : a journal of neurology.

[52]  F. Niccolini,et al.  Neuroimaging in Huntington's disease. , 2014, World journal of radiology.

[53]  Guido F. Schauer,et al.  Neuroanatomical correlates of behavioural disorders in dementia. , 2005, Brain : a journal of neurology.

[54]  Klaus Seppi,et al.  Proposed neuroimaging criteria for the diagnosis of multiple system atrophy , 2009, Movement disorders : official journal of the Movement Disorder Society.

[55]  A. King,et al.  The question of familial meningiomas and schwannomas: , 2000, Neurology.

[56]  D. Aarsland,et al.  Changes in motor subtype and risk for incident dementia in Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[57]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[58]  Dorothy Forbes,et al.  Exercise programs for people with dementia. , 2015, The Cochrane database of systematic reviews.

[59]  S. Prusiner,et al.  Transmission of multiple system atrophy prions to transgenic mice , 2013, Proceedings of the National Academy of Sciences.

[60]  C. Jack,et al.  MRI correlates of neurofibrillary tangle pathology at autopsy , 2008, Neurology.

[61]  Y. Hirayasu,et al.  Clinical profiles of dementia with Lewy bodies with and without Alzheimer's disease‐like hypometabolism , 2015, International journal of geriatric psychiatry.

[62]  J. Weuve,et al.  2016 Alzheimer's disease facts and figures , 2016 .

[63]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[64]  W. Poewe,et al.  Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group , 2014, Movement disorders : official journal of the Movement Disorder Society.

[65]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[66]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[67]  O. Suchowersky,et al.  Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology , 2013, Neurology.

[68]  M. T. Pellecchia,et al.  Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry , 2010, Movement disorders : official journal of the Movement Disorder Society.

[69]  I G McKeith,et al.  MRI volumetric study of dementia with Lewy bodies , 2000, Neurology.

[70]  W. Kamphorst,et al.  Frontal presentation in progressive supranuclear palsy , 2007, Neurology.

[71]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[72]  D. Dickson Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration , 1999, Journal of Neurology.

[73]  J. Hoffman,et al.  FDG PET imaging in patients with pathologically verified dementia. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[74]  G. Frisoni,et al.  Detection of grey matter loss in mild Alzheimer's disease with voxel based morphometry , 2002, Journal of neurology, neurosurgery, and psychiatry.

[75]  B. Lippitz,et al.  Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. , 1994, Neurosurgery.

[76]  H. Kolb,et al.  [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.

[77]  D. F. Brown,et al.  Progressive supranuclear palsy with dementia: cortical pathology. , 1999, Journal of neuropathology and experimental neurology.

[78]  K. Rankin,et al.  The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. , 2011, The Journal of clinical psychiatry.

[79]  G. Borasio,et al.  Inappropriate sexual behaviour in a case of ALS and FTD: Successful treatment with sertraline , 2007, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[80]  A. Benabid,et al.  Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. , 1987, Applied neurophysiology.

[81]  J. Obeso,et al.  Hardware complications in deep brain stimulation: electrode impedance and loss of clinical benefit. , 2012, Parkinsonism & related disorders.

[82]  J. Matsumoto,et al.  Clinical features and autonomic testing predict survival in multiple system atrophy. , 2015, Brain : a journal of neurology.

[83]  A. Hofman,et al.  Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. , 2000, Neurology.

[84]  M. MacDonald,et al.  CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion , 2012, Neurology.

[85]  Bastiaan R Bloem,et al.  Gender differences in Parkinson’s disease , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[86]  I. Litvan,et al.  Tau genotype: No effect on onset, symptom severity, or survival in progressive supranuclear palsy , 2001, Neurology.

[87]  I G McKeith,et al.  Atrophy of the putamen in dementia with Lewy bodies but not Alzheimer’s disease , 2003, Neurology.

[88]  A. Drzezga,et al.  Cerebral Metabolic Dysfunction in Patients with Dementia with Lewy Bodies and Visual Hallucinations , 2008, Dementia and Geriatric Cognitive Disorders.

[89]  E M Wijsman,et al.  Influence of apolipoprotein E genotype on the transmission of Alzheimer disease in a community-based sample. , 1996, American journal of human genetics.

[90]  Jeffrey L. Cummings,et al.  Neuropsychiatric aspects of progressive supranuclear palsy , 1996, Neurology.

[91]  Alan J. Thomas,et al.  Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.

[92]  C. Rowe,et al.  Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[93]  Günther Deuschl,et al.  Rivastigmine for dementia associated with Parkinson's disease. , 2004, The New England journal of medicine.

[94]  John Hardy,et al.  Parkinson's disease , 2009, The Lancet.

[95]  Archana Singh-Manoux,et al.  Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[96]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[97]  Maria Luisa Gorno-Tempini,et al.  Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. , 2006, Archives of neurology.

[98]  J. Schneider,et al.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration , 2007, Acta Neuropathologica.

[99]  Keith A. Johnson,et al.  Brain amyloid and cognition in Lewy body diseases , 2012, Movement disorders : official journal of the Movement Disorder Society.

[100]  Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. , 1997, The Journal of clinical psychiatry.

[101]  J. Trojanowski,et al.  Mutations in COQ2 in familial and sporadic multiple-system atrophy. , 2013, The New England journal of medicine.

[102]  J. Trojanowski,et al.  Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. , 2011, Archives of neurology.

[103]  J. Trojanowski,et al.  Clinicopathological correlations in corticobasal degeneration , 2011, Annals of neurology.

[104]  Benjamin F. J. Verhaaren,et al.  Is dementia incidence declining? , 2012, Neurology.

[105]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[106]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[107]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[108]  M. Hayden,et al.  Multisource ascertainment of Huntington disease in Canada: Prevalence and population at risk , 2014, Movement disorders : official journal of the Movement Disorder Society.

[109]  B L Miller,et al.  Patterns of brain atrophy in frontotemporal dementia and semantic dementia , 2002, Neurology.

[110]  K. Marder,et al.  Risk of Parkinson's disease among first-degree relatives , 1996, Neurology.

[111]  Hiroaki Kazui,et al.  Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E epsilon4 allele. , 2002, Annals of neurology.

[112]  K. Blennow,et al.  CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study , 2015, Alzheimer's & Dementia.

[113]  S. Gilman,et al.  Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy , 1994, Annals of neurology.

[114]  J. Brandt,et al.  The association of CAG repeat length with clinical progression in Huntington disease , 2006, Neurology.

[115]  C. van Broeckhoven,et al.  The genetics and neuropathology of frontotemporal lobar degeneration , 2012, Acta Neuropathologica.

[116]  C. Cusin,et al.  Rapid improvement of depression and psychotic symptoms in Huntington's disease: a retrospective chart review of seven patients treated with electroconvulsive therapy. , 2013, General hospital psychiatry.

[117]  Guy B. Williams,et al.  Patterns of Frontal Lobe Atrophy in Frontotemporal Dementia: A Volumetric MRI Study , 2006, Dementia and Geriatric Cognitive Disorders.

[118]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[119]  J. Jankovic,et al.  Parkinson disease subtypes. , 2014, JAMA neurology.

[120]  M. Mendez,et al.  Accuracy of the clinical evaluation for frontotemporal dementia. , 2007, Archives of neurology.

[121]  D. Rubinsztein,et al.  Huntington's Disease: Mechanisms of Pathogenesis and Therapeutic Strategies. , 2017, Cold Spring Harbor perspectives in medicine.

[122]  Sonja W. Scholz,et al.  Genetic players in multiple system atrophy: unfolding the nature of the beast , 2011, Neurobiology of Aging.

[123]  M. Prince,et al.  Epidemiology of dementias and Alzheimer's disease. , 2012, Archives of medical research.

[124]  I. McKeith,et al.  Benefits of rivastigmine on attention in dementia associated with Parkinson disease , 2005, Neurology.

[125]  K P Bhatia,et al.  The role of DAT-SPECT in movement disorders , 2008, Journal of Neurology, Neurosurgery & Psychiatry.

[126]  Howard J. Rosen,et al.  Distinctive Neuropsychological Patterns in Frontotemporal Dementia, Semantic Dementia, And Alzheimer Disease , 2003, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology.

[127]  R. Petersen,et al.  Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia , 1999, Neurology.

[128]  C. Lyketsos,et al.  Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[129]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[130]  J. Rowe,et al.  Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes , 2016, Neurology.

[131]  C. D. de Jager,et al.  APOE alleles predict the rate of cognitive decline in Alzheimer disease , 2005, Neurology.

[132]  M. Dale,et al.  Anxiety in Huntington's Disease. , 2015, The Journal of neuropsychiatry and clinical neurosciences.

[133]  B. Bloem,et al.  CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders , 2015, Front. Neurol..

[134]  D. Eidelberg,et al.  Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[135]  James Robert Brašić,et al.  In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.

[136]  H. Kretzschmar,et al.  Definite multiple system atrophy in a German family , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[137]  C. Jack,et al.  Voxel-based morphometry in autopsy proven PSP and CBD , 2008, Neurobiology of Aging.

[138]  A. Porcellini,et al.  Short-term effects of olanzapine in Huntington disease. , 2001, Neuropsychiatry, neuropsychology, and behavioral neurology.

[139]  C. Ross,et al.  Huntington's disease: from molecular pathogenesis to clinical treatment , 2011, The Lancet Neurology.

[140]  A. Spector,et al.  Cognitive stimulation to improve cognitive functioning in people with dementia. , 2012, The Cochrane database of systematic reviews.

[141]  Karen M Rodrigue,et al.  Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. , 2015, JAMA.

[142]  Vincent A Magnotta,et al.  Longitudinal change in regional brain volumes in prodromal Huntington disease , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[143]  R. Mayeux,et al.  Familial aggregation of dementia with Lewy bodies. , 2011, Archives of neurology.

[144]  V. Pankratz,et al.  Risk factors for dementia with Lewy bodies , 2013, Neurology.

[145]  D. Galimberti,et al.  Genetics of Frontotemporal Lobar Degeneration , 2012, Front. Neur..

[146]  M. Breteler,et al.  Familial aggregation of parkinsonism in progressive supranuclear palsy , 2009, Neurology.

[147]  L. Golbe,et al.  Prevalence and natural history of progressive supranuclear palsy , 1988, Neurology.

[148]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[149]  D. Paviour,et al.  Commentary on: Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism, by , 2005 .

[150]  H. Heinsen,et al.  Cortical and striatal neurone number in Huntington's disease , 2004, Acta Neuropathologica.

[151]  Lisa Kuramoto,et al.  Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. , 2004, Archives of neurology.

[152]  P. Rochon,et al.  Antidepressants for agitation and psychosis in dementia. , 2011, The Cochrane database of systematic reviews.

[153]  E. Tolosa,et al.  Long lasting pure freezing of gait preceding progressive supranuclear palsy: A clinicopathological study , 2007, Movement disorders : official journal of the Movement Disorder Society.

[154]  Mark D'Esposito,et al.  Progressive Nonfluent Aphasia: Language, Cognitive, and PET Measures Contrasted with Probable Alzheimer's Disease , 1996, Journal of Cognitive Neuroscience.

[155]  M. Tsolaki,et al.  Rivastigmine for Alzheimer's disease. , 2000, The Cochrane database of systematic reviews.

[156]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[157]  R. D. de Haan,et al.  GPi vs STN deep brain stimulation for Parkinson disease , 2016, Neurology.

[158]  D J Brooks,et al.  DLB and PDD boundary issues , 2007, Neurology.

[159]  I. Mackenzie,et al.  TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia , 2010, The Lancet Neurology.

[160]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[161]  R. Newcombe A life table for onset of Huntington's chorea , 1981, Annals of human genetics.

[162]  David Mann,et al.  Frontotemporal lobar degeneration: clinical and pathological relationships , 2007, Acta Neuropathologica.

[163]  C. Lomen‐Hoerth,et al.  Clinical Phenomenology and Neuroimaging Correlates in ALS-FTD , 2011, Journal of Molecular Neuroscience.

[164]  M. Farrer,et al.  MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy , 2011, Neurology.

[165]  Bruce Fischl,et al.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. , 2008, Brain : a journal of neurology.

[166]  C. Aguilar,et al.  Multivariate classification of patients with Alzheimer’s and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study , 2013, Journal of Neurology.

[167]  K. Josephs Capgras syndrome and its relationship to neurodegenerative disease. , 2007, Archives of neurology.

[168]  Anthony E. Lang,et al.  Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD , 2016, Nature Reviews Neurology.

[169]  M. T. Pellecchia,et al.  Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG) , 2006, Movement disorders : official journal of the Movement Disorder Society.

[170]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[171]  Margaret A. Pericak-Vance,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .

[172]  R. Nussbaum Genetics of Synucleinopathies. , 2018, Cold Spring Harbor perspectives in medicine.

[173]  Antonio Daniele,et al.  Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation , 2012, The Lancet Neurology.

[174]  F. Pasquier,et al.  Frontotemporal Dementia: A Randomised, Controlled Trial with Trazodone , 2004, Dementia and Geriatric Cognitive Disorders.

[175]  G. Chiro,et al.  Computed tomography, magnetic resonance imaging and positron emission tomography with [18F] fluorodeoxyglucose in multiple system atrophy and pure autonomic failure , 1991, Clinical Autonomic Research.

[176]  William W. Seeley,et al.  Anterior insula degeneration in frontotemporal dementia , 2010, Brain Structure and Function.

[177]  J. Hodges,et al.  Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. , 2010, Archives of neurology.

[178]  I. Mackenzie The Neuropathology of FTD Associated With ALS , 2007, Alzheimer disease and associated disorders.

[179]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[180]  Susanne Pirker,et al.  Dopamine transporter imaging in autopsy‐confirmed Parkinson's disease and multiple system atrophy , 2012, Movement disorders : official journal of the Movement Disorder Society.

[181]  J. O'Brien,et al.  Patterns of gray matter atrophy in dementia with Lewy bodies: a voxel-based morphometry study , 2011, International Psychogeriatrics.

[182]  M. Hayden,et al.  The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. , 1997, American journal of human genetics.

[183]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[184]  B. Miller,et al.  Neuropsychological, behavioral, and anatomical evolution in right temporal variant frontotemporal dementia: A longitudinal and post-mortem single case analysis , 2014, Neurocase.

[185]  Y Ben-Shlomo,et al.  Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study , 1999, The Lancet.

[186]  J. O'Brien,et al.  The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies , 2013, Psychological Medicine.

[187]  F. Tison,et al.  Prevalence of multiple system atrophy , 2000, The Lancet.

[188]  M. Riepe,et al.  Memantine in Moderate-to-severe Alzheimer's Disease , 2006 .

[189]  B. Miller,et al.  Frontotemporal lobar degeneration: demographic characteristics of 353 patients. , 2005, Archives of neurology.

[190]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[191]  D. Maraganore,et al.  Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990 , 1997, Neurology.

[192]  J. Hodges,et al.  Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. , 2010, Brain : a journal of neurology.

[193]  C. Geula,et al.  Clinically concordant variations of Alzheimer pathology in aphasic versus amnestic dementia. , 2012, Brain : a journal of neurology.

[194]  C. Morris,et al.  Influence of the amyloid precursor protein locus on dementia in Down syndrome , 2004, Neurology.

[195]  S. Seneca,et al.  Early onset Huntington disease: a neuronal degeneration syndrome , 2004, European Journal of Pediatrics.

[196]  N. Jetté,et al.  The incidence and prevalence of Huntington's disease: A systematic review and meta‐analysis , 2012, Movement disorders : official journal of the Movement Disorder Society.

[197]  D. Jolley,et al.  Cost benefits of a medically supervised day treatment program for patients with Alzheimer's disease and other forms of dementia , 1989 .

[198]  J. Jankovic,et al.  Variable expression of Parkinson's disease , 1990, Neurology.

[199]  B L Miller,et al.  A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD , 2005, Neurology.

[200]  J. Morris,et al.  Familial dementia with Lewy bodies: clinicopathologic analysis of two kindreds. , 2002, Neurology.

[201]  Gunhild Waldemar,et al.  Evidence-based Evaluation of Magnetic Resonance Imaging as a Diagnostic Tool in Dementia Workup , 2005, Topics in magnetic resonance imaging : TMRI.

[202]  I. McKeith,et al.  Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[203]  Alan Thomas,et al.  Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross‐sectional comparative study , 2003, Movement disorders : official journal of the Movement Disorder Society.

[204]  R. Roos,et al.  Huntington's disease: a clinical review , 2010, Orphanet journal of rare diseases.

[205]  Vincenzo Bonifati,et al.  The genetics of Parkinson's disease: Progress and therapeutic implications , 2013, Movement disorders : official journal of the Movement Disorder Society.

[206]  R. Reilmann,et al.  Diagnostic criteria for Huntington's disease based on natural history , 2014, Movement disorders : official journal of the Movement Disorder Society.

[207]  R. Coleman,et al.  Use of Florbetapir-PET for Imaging-Amyloid Pathology , 2011 .

[208]  Y. Abe,et al.  Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. , 2002, Brain : a journal of neurology.

[209]  I Litvan,et al.  Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination , 1998, Journal of neurology, neurosurgery, and psychiatry.

[210]  D. Knopman,et al.  Estimating the Number of Persons with Frontotemporal Lobar Degeneration in the US Population , 2011, Journal of Molecular Neuroscience.

[211]  Serggio C. Lanata,et al.  The behavioural variant frontotemporal dementia (bvFTD) syndrome in psychiatry , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[212]  V. Sossi,et al.  Age‐specific progression of nigrostriatal dysfunction in Parkinson's disease , 2011, Annals of neurology.

[213]  M. Albert,et al.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. , 1989, JAMA.

[214]  Norbert Schuff,et al.  Patterns of cerebral atrophy in primary progressive aphasia. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[215]  E. Tolosa,et al.  Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force , 2007, Movement disorders : official journal of the Movement Disorder Society.

[216]  C. Geula,et al.  Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia. , 2014, Brain : a journal of neurology.

[217]  N. Quinn,et al.  Survival of patients with pathologically proven multiple system atrophy , 1997, Neurology.

[218]  Johannes C. Klein,et al.  Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo , 2010, Neurology.

[219]  I Litvan,et al.  Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.

[220]  Mark Hallett,et al.  Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.

[221]  Sonja W. Scholz,et al.  A genome-wide association study in multiple system atrophy , 2016, Neurology.

[222]  C Cadilhac,et al.  Cognitive impairment in motor neuron disease with bulbar onset , 2001, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[223]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[224]  J. Quinn,et al.  Changes in premorbid brain volume predict Alzheimer’s disease pathology , 2003, Neurology.

[225]  C. Brayne,et al.  A systematic review of prevalence and incidence studies of dementia with Lewy bodies. , 2005, Age and ageing.

[226]  J. Hodges,et al.  Survival in frontotemporal dementia , 2003, Neurology.

[227]  R. Hamilton,et al.  Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry , 2000, Brain pathology.

[228]  J. Olin,et al.  Galantamine for Alzheimer's disease. , 2004, The Cochrane database of systematic reviews.

[229]  J. Hardy,et al.  Milestones in PD genetics , 2011, Movement disorders : official journal of the Movement Disorder Society.

[230]  R J Harvey,et al.  Donepezil for dementia due to Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.

[231]  Douglas Galasko,et al.  Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study , 2000, International journal of geriatric psychiatry.

[232]  Nancy Johnson,et al.  Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia , 2008, Annals of neurology.

[233]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[234]  Kazuhiko Yanai,et al.  Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. , 2014, Brain : a journal of neurology.

[235]  N. Pouratian,et al.  Deep brain stimulation for the treatment of Parkinson's disease: efficacy and safety. , 2012, Degenerative neurological and neuromuscular disease.

[236]  G. Wenning Placebo-Controlled Trial of Amantadine in Multiple-System Atrophy , 2005, Clinical neuropharmacology.

[237]  J. Jankovic,et al.  Functional decline in Parkinson disease. , 2001, Archives of neurology.

[238]  Murray Grossman,et al.  Clinical diagnostic criteria and classification controversies in frontotemporal lobar degeneration , 2013, International review of psychiatry.

[239]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[240]  A. Kertesz,et al.  The cognitive profile of posterior cortical atrophy , 2006 .

[241]  B. Bloem,et al.  CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. , 2014, Parkinsonism & related disorders.

[242]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[243]  Eric E. Smith,et al.  The Prevalence and Incidence of Frontotemporal Dementia: a Systematic Review , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[244]  P. Kempster,et al.  Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. , 2008, Brain : a journal of neurology.

[245]  D. Craufurd,et al.  Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease. , 2012, The Journal of neuropsychiatry and clinical neurosciences.

[246]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[247]  Andrew Kertesz,et al.  The evolution and pathology of frontotemporal dementia. , 2005, Brain : a journal of neurology.

[248]  C. Adler,et al.  MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI , 2011, Movement disorders : official journal of the Movement Disorder Society.

[249]  H. Markowitsch,et al.  Amnesic disorders , 2012, The Lancet.

[250]  Clifford R Jack,et al.  Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. , 2007, Brain : a journal of neurology.

[251]  W. Jagust,et al.  Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia , 2008, Annals of neurology.

[252]  Clifford R. Jack,et al.  FDG PET and MRI in Logopenic Primary Progressive Aphasia versus Dementia of the Alzheimer’s Type , 2013, PloS one.

[253]  R. Brookmeyer,et al.  APOE genotype and survival in men and women with Alzheimer’s disease , 2002, Neurology.

[254]  B. Dubois,et al.  Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. , 1999, American journal of human genetics.

[255]  D. Neary,et al.  Classification and pathology of primary progressive aphasia , 2013, Neurology.

[256]  William T. Hu,et al.  Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease , 2011, Annals of neurology.

[257]  D. Hernandez,et al.  Genome-wide estimate of the heritability of Multiple System Atrophy. , 2016, Parkinsonism & related disorders.

[258]  Günther Deuschl,et al.  Red flags for multiple system atrophy , 2008, Movement disorders : official journal of the Movement Disorder Society.

[259]  J. Holton,et al.  The neuropathology, pathophysiology and genetics of multiple system atrophy , 2012, Neuropathology and applied neurobiology.

[260]  M. Rodríguez Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma. , 1998, Acta radiologica. Supplementum.

[261]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[262]  R. Olney,et al.  The effects of executive and behavioral dysfunction on the course of ALS , 2005, Neurology.

[263]  K. Jellinger,et al.  Pharmacological therapy in progressive supranuclear palsy. , 1998, Archives of neurology.

[264]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[265]  M. Carrillo,et al.  Imaging dementia: Evidence for amyloid scanning (IDEAS)—a national study to evaluate the clinical utility of amyloid PET , 2015, Alzheimer's & Dementia.

[266]  J. Baron,et al.  In Vivo Mapping of Gray Matter Loss with Voxel-Based Morphometry in Mild Alzheimer's Disease , 2001, NeuroImage.

[267]  C. Rowe,et al.  Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism , 2008, The Lancet Neurology.

[268]  Udo Rüb,et al.  Degeneration of the Cerebellum in Huntington's Disease (HD): Possible Relevance for the Clinical Picture and Potential Gateway to Pathological Mechanisms of the Disease Process , 2013, Brain pathology.

[269]  G. Wenning,et al.  Multiple system atrophy. , 2013, Handbook of clinical neurology.

[270]  B. Miller,et al.  The logopenic/phonological variant of primary progressive aphasia , 2008, Neurology.

[271]  I. McKeith,et al.  Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study , 2007, The Lancet Neurology.

[272]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[273]  Janice E. Knoefel,et al.  Apolipoprotein E element 4 association with dementia in a population-based study , 1996, Neurology.

[274]  S. DeKosky,et al.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease , 2008, Brain : a journal of neurology.

[275]  Jane S. Paulsen Cognitive Impairment in Huntington Disease: Diagnosis and Treatment , 2011, Current neurology and neuroscience reports.

[276]  J. Neuhaus,et al.  Comparison of family histories in FTLD subtypes and related tauopathies , 2005, Neurology.

[277]  R. Perry,et al.  Non-Picks frontotemporal dementia imitating schizophrenia in a 22-year-old man , 2003, Journal of Neurology.

[278]  B. Miller,et al.  Distinct MRI Atrophy Patterns in Autopsy-Proven Alzheimer's Disease and Frontotemporal Lobar Degeneration , 2008, American journal of Alzheimer's disease and other dementias.

[279]  C. Jack,et al.  Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.

[280]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[281]  M. Diamond,et al.  Prion-like mechanisms in neurodegenerative diseases , 2010, Nature Reviews Neuroscience.

[282]  Peter L. Lantos,et al.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) , 1989, Journal of the Neurological Sciences.

[283]  C. Jack,et al.  Symmetric corticobasal degeneration (S-CBD). , 2010, Parkinsonism & related disorders.

[284]  Maria Luisa Gorno-Tempini,et al.  Structural anatomy of empathy in neurodegenerative disease. , 2006, Brain : a journal of neurology.

[285]  G. Rabinovici,et al.  Atypical Alzheimer's disease , 2016 .

[286]  M. Mesulam,et al.  Primary progressive aphasia--a language-based dementia. , 2003, The New England journal of medicine.

[287]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[288]  L. Tan,et al.  Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[289]  Maria Luisa Gorno-Tempini,et al.  Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. , 2008, Archives of neurology.

[290]  Brit Mollenhauer,et al.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.

[291]  Jane S. Paulsen,et al.  Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study , 2014, The Lancet Neurology.

[292]  T. Ferman,et al.  Family history of dementia is a risk factor for Lewy body disease , 2006, Neurology.

[293]  Jennifer L. Whitwell,et al.  Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. , 2006, Brain : a journal of neurology.

[294]  B. Boeve,et al.  Incidence of dementia with Lewy bodies and Parkinson disease dementia. , 2013, JAMA neurology.

[295]  R. Coleman,et al.  Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.

[296]  A. Lang,et al.  The many faces of corticobasal degeneration. , 2007, Parkinsonism & related disorders.

[297]  K. Davis,et al.  Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. , 1994, Neuroreport.

[298]  D. Geschwind,et al.  Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[299]  Alexandra Durr,et al.  How much phenotypic variation can be attributed to parkin genotype? , 2003, Annals of neurology.

[300]  R. Brookmeyer,et al.  Sources of variability in prevalence rates of Alzheimer's disease. , 1995, International journal of epidemiology.

[301]  H. Rickards,et al.  Changes in mental state and behaviour in Huntington's disease. , 2016, The lancet. Psychiatry.

[302]  C. Pantelis,et al.  Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. , 2009, The British journal of psychiatry : the journal of mental science.

[303]  The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis , 2015, Neurotherapeutics.

[304]  E. Londos,et al.  Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial , 2009, The Lancet Neurology.

[305]  Rajesh Pahwa,et al.  Surgical and hardware complications of subthalamic stimulation , 2004, Neurology.

[306]  A. Hofman,et al.  The impact of APOE on myocardial infarction, stroke, and dementia , 2004, Neurology.

[307]  J R Hodges,et al.  Incidence of early-onset dementias in Cambridgeshire, United Kingdom , 2008, Neurology.

[308]  Jane S. Paulsen,et al.  Huntington disease: natural history, biomarkers and prospects for therapeutics , 2014, Nature Reviews Neurology.

[309]  R. Kopito,et al.  Prion-Like Characteristics of Polyglutamine-Containing Proteins. , 2018, Cold Spring Harbor perspectives in medicine.

[310]  Dennis W. Dickson,et al.  Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau) , 2011, Journal of Molecular Neuroscience.

[311]  E. Tolosa,et al.  Clinical diagnostic criteria for dementia associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[312]  J. Trojanowski,et al.  The North American Multiple System Atrophy Study Group , 2005, Journal of Neural Transmission.

[313]  A. Young,et al.  A polymorphic DNA marker genetically linked to Huntington's disease , 1983, Nature.

[314]  R. Mayeux,et al.  Epidemiology of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[315]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[316]  R. Nussbaum,et al.  Alzheimer's disease and Parkinson's disease. , 2003, The New England journal of medicine.

[317]  P. Barreira,et al.  Obsessive-compulsive disorders in Pick's disease. , 1994, The Journal of neuropsychiatry and clinical neurosciences.

[318]  S. Prusiner Biology and genetics of prions causing neurodegeneration. , 2013, Annual review of genetics.

[319]  A. Young,et al.  Interrater agreement in the assessment of motor manifestations of Huntington's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[320]  R. Petersen,et al.  Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States , 2011, Alzheimer's & Dementia.

[321]  Günther Deuschl,et al.  The natural history of multiple system atrophy: a prospective European cohort study , 2013, The Lancet Neurology.

[322]  J. Trojanowski,et al.  A harmonized classification system for FTLD-TDP pathology , 2011, Acta Neuropathologica.

[323]  Martin Knapp,et al.  Donepezil and memantine for moderate-to-severe Alzheimer's disease. , 2012, The New England journal of medicine.

[324]  N. Quinn,et al.  Multiple system atrophy--the nature of the beast. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[325]  Hiroaki Kazui,et al.  Accelerated hippocampal atrophy in Alzheimer's disease with apolipoprotein E ε4 allele , 2002 .

[326]  M. Grossman,et al.  Primary progressive aphasia: clinicopathological correlations , 2010, Nature Reviews Neurology.

[327]  Arthur W Toga,et al.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. , 2013, JAMA neurology.

[328]  R. McShane,et al.  Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review , 2012, BMJ Open.

[329]  Jennifer Harris,et al.  Pathology in Primary Progressive Aphasia Syndromes , 2014, Current Neurology and Neuroscience Reports.

[330]  Roberta F. White,et al.  Late onset of Huntington's disease. , 1985, Journal of neurology, neurosurgery, and psychiatry.